Stockscreener 앱 받기
23.28
2.59%
-0.62
시간 외 거래:
23.28
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Mineralys reports 2025 results, advances hypertension drug review - MSN
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com UK
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Insider Monkey
Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com - Investing.com Australia
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com Nigeria
BofA raises Mineralys Therapeutics stock price target on NDA progress By Investing.com - Investing.com Nigeria
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha
Stifel reiterates Buy rating on Mineralys stock, $52 target By Investing.com - Investing.com Canada
BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - MSN
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Bitget
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c) - TipRanks
Mineralys Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast - Investing.com
Mineralys Therapeutics and Lorundrostat: Clinical Development, Competitive Landscape, and Regulatory Overview for Hypertension Therapy 2122273536 - Minichart
1.20%
0.06%
자본화:
|
볼륨(24시간):